F1000Research
(Jul 2014)
Case Report: Reversible cabergoline-associated cardiac valvulopathy post drug discontinuation [v1; ref status: indexed, http://f1000r.es/2jm]
Chris G. Yedinak,
Shirley McCartney,
Troy H. Dillard,
Kevin S. Wei,
Maria Fleseriu
Affiliations
Chris G. Yedinak
Department of Neurological Surgery, Oregon Health & Science University, Portland, Oregon, 97239, USA
Shirley McCartney
Department of Neurological Surgery, Oregon Health & Science University, Portland, Oregon, 97239, USA
Troy H. Dillard
Department of Medicine, Division of Endocrinology, Diabetes and Clinical Nutrition, Oregon Health & Science University, Portland, Oregon, 97239, USA
Kevin S. Wei
Department of Cardiovascular Medicine, Oregon Health & Science University, Portland, Oregon, 97239, USA
Maria Fleseriu
Department of Medicine, Division of Endocrinology, Diabetes and Clinical Nutrition, Oregon Health & Science University, Portland, Oregon, 97239, USA
DOI
https://doi.org/10.12688/f1000research.3062.1
Journal volume & issue
Vol. 3
Abstract
Read online
We present a case of a 21 year old male patient diagnosed with a 2.2 cm prolactin-secreting adenoma in contact with the optic chiasm. The patient was treated with up to 6mg/week of cabergoline (total cumulative dose 814 mg) and developed mild valvulopathy. Valvulopathy was subsequently reversed after discontinuation of cabergoline therapy.
Keywords
WeChat QR code
Close
